Cantor Fitzgerald Predicts REGN FY2025 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Regeneron Pharmaceuticals in a research note issued on Tuesday, April 22nd. Cantor Fitzgerald analyst C. Gould expects that the biopharmaceutical company will post earnings of $26.38 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $695.00 target price on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share.

REGN has been the topic of a number of other research reports. Sanford C. Bernstein reduced their price objective on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Bank of America cut their price target on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a report on Thursday, April 17th. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. UBS Group lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a “buy” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $949.60.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $599.76 on Thursday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The firm has a 50-day simple moving average of $638.93 and a 200-day simple moving average of $728.60. Regeneron Pharmaceuticals has a 52 week low of $525.99 and a 52 week high of $1,211.20. The stock has a market capitalization of $65.57 billion, a price-to-earnings ratio of 15.67, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm earned $11.86 EPS. The company’s revenue for the quarter was up 10.3% on a year-over-year basis.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Pamalican Asset Management Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $4,915,000. Intact Investment Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $356,000. Rhenman & Partners Asset Management AB boosted its stake in shares of Regeneron Pharmaceuticals by 11.4% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 43,457 shares of the biopharmaceutical company’s stock valued at $30,956,000 after buying an additional 4,457 shares in the last quarter. Principal Financial Group Inc. raised its position in Regeneron Pharmaceuticals by 1.7% in the third quarter. Principal Financial Group Inc. now owns 173,092 shares of the biopharmaceutical company’s stock worth $181,961,000 after acquiring an additional 2,828 shares in the last quarter. Finally, Fagan Associates Inc. lifted its holdings in Regeneron Pharmaceuticals by 42.2% in the fourth quarter. Fagan Associates Inc. now owns 12,923 shares of the biopharmaceutical company’s stock valued at $9,205,000 after acquiring an additional 3,832 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.59%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.